Nitrogen-containing macrocyclic compounds, pharmaceutical composition and use thereof

Abstract

a solvate, a pharmaceutically acceptable salt thereof or a solvate of the pharmaceutically acceptable salt thereof. The compounds of the present disclosure are orally bioavailable pan-RAS inhibitors which can target a wider range of RAS mutations than traditional mutant-selective RAS inhibitors, and have high exposure, long half-life and good pharmacokinetic properties, may be useful for the treatment of RAS-driven cancers and effective in patients who have not responded to other therapies.

Images